Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Biomed Pharmacother. 2021 Jan;133:111093. doi: 10.1016/j.biopha.2020.111093. Epub 2020 Dec 8.
Deleted in lymphocytic leukemia 2" (DLEU2) is a long non-coding transcript with several splice variants. It has been identified through a comprehensive sequencing of a commonly deleted region in leukemia i.e. the 13q14 region. Afterwards, different investigations reported up-regulation of this long non-coding RNA in several types of cancers. Up-regulation of DLEU2 has been shown to determine poor survival in esophageal, pancreatic, laryngeal, renal, cervical and lung cancers. However, the diagnostic power of DLUE2 has only assessed in two studies; only one them exhibiting promising results. A limitation of most of studies is that they did not differentiate between transcript variants of this lncRNA. Therefore, it is not possible to attribute the observed functions to a certain alternate transcript. In this manuscript, we discuss the results of these studies in three different sections based on the type of experiments.
缺失在淋巴细胞白血病 2 号（DLEU2）是一个具有几个剪接变异体的长非编码转录本。它是通过对白血病中常见缺失区域（即 13q14 区域）的全面测序而被识别的。此后，不同的研究报告称这种长非编码 RNA 在几种类型的癌症中上调。DLEU2 的上调已被证明与食管癌、胰腺癌、喉癌、肾癌、宫颈癌和肺癌的不良预后相关。然而，DLUE2 的诊断能力仅在两项研究中进行了评估；其中只有一项研究显示出有希望的结果。大多数研究的一个局限性是，它们没有区分这种 lncRNA 的转录变体。因此，无法将观察到的功能归因于特定的替代转录本。在本文中，我们根据实验类型将这些研究的结果分为三个不同的部分进行讨论。
